IGF-1 and Cancer Risk: What the Evidence Shows

Growth Hormone Peptide Safety

395,000 Participants

The UK Biobank analysis of nearly 395,000 participants confirmed that higher circulating IGF-1 concentrations are associated with increased risk of colorectal, breast, and prostate cancer.

Oxford Cancer Epidemiology Unit, Cancer Research, 2020

Oxford Cancer Epidemiology Unit, Cancer Research, 2020

View as image

Insulin-like growth factor 1 (IGF-1) is the primary mediator of growth hormone's effects throughout the body. When growth hormone stimulates the liver, the liver produces IGF-1, which then drives cell growth, proliferation, and survival in virtually every tissue. This same biology that makes IGF-1 essential for normal development creates a theoretical concern: if IGF-1 promotes cell growth, could elevated IGF-1 also promote the growth of cancer cells?^[1] For the pillar article on growth hormone peptide safety, see MK-677 and insulin resistance.

This question matters because growth hormone secretagogues (GHRPs, GHRH analogs, MK-677) are among the most widely used peptides in the wellness and bodybuilding communities. These compounds work by elevating growth hormone, which in turn elevates IGF-1. If elevated IGF-1 increases cancer risk, then chronic use of growth hormone peptides carries an oncological concern that users and researchers need to understand. This article examines what the epidemiological, mechanistic, and clinical evidence actually shows.

How IGF-1 Promotes Cell Growth

IGF-1 binds to the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor present on virtually all cell types. Receptor activation triggers two major intracellular signaling cascades: the PI3K/AKT/mTOR pathway (promoting cell survival and protein synthesis) and the RAS/MAPK pathway (promoting cell proliferation). Together, these pathways drive cell growth, inhibit programmed cell death (apoptosis), and stimulate angiogenesis.^[1]

In normal physiology, this signaling is tightly regulated. IGF-1 bioavailability is controlled by six IGF binding proteins (IGFBP-1 through IGFBP-6) that sequester IGF-1 in circulation, limiting how much reaches cell-surface receptors. IGFBP-3 carries approximately 80% of circulating IGF-1 and acts as a brake on IGF-1 signaling. When this regulatory balance is disrupted (through elevated GH, obesity, insulin resistance, or exogenous GH peptide use), the increased free IGF-1 reaching receptors theoretically promotes the growth of both normal and potentially malignant cells.

Chuard et al. (2025) demonstrated that even viruses exploit this system: viral insulin/IGF-like peptides (VILPs) from Iridoviridae inhibit IGF-1 receptor signaling to create conditions favorable for viral replication.^[4] This finding underscores how fundamental the IGF-1 axis is to cellular growth control and how its manipulation, whether by viruses, metabolic disease, or exogenous peptides, can alter cell behavior.

The Epidemiological Evidence

Large Cohort Studies

The strongest epidemiological evidence comes from the UK Biobank analysis of approximately 395,000 participants, which confirmed that higher circulating IGF-1 concentrations are associated with increased risk of several cancers. The associations were strongest for colorectal cancer, breast cancer (particularly in premenopausal women), and prostate cancer, with risk increases of approximately 9-15% per standard deviation increase in IGF-1 levels.

These are observational associations, not proof of causation. People with higher IGF-1 levels differ from those with lower levels in many ways (body composition, diet, physical activity, insulin sensitivity) that could confound the association. Mendelian randomization studies, which use genetic variants associated with IGF-1 levels as instruments, have partially addressed this concern and generally support a causal relationship for colorectal and prostate cancer, though the evidence for breast cancer is less consistent.

The magnitude of risk deserves context. A 9-15% increase per standard deviation of IGF-1 is a modest effect size. For comparison, smoking increases lung cancer risk by 1,500-3,000%. Obesity increases colorectal cancer risk by 30-50%. The IGF-1-cancer association is real but operates at a lower magnitude than most established cancer risk factors. It represents a population-level statistical association, not an individual-level certainty. Many people with high IGF-1 levels will never develop cancer, and many people with low IGF-1 levels will. The association shifts probabilities across populations, not outcomes for individual people.

The Laron Syndrome Natural Experiment

The most compelling evidence comes from people with Laron syndrome, a genetic condition caused by growth hormone receptor deficiency. These individuals produce growth hormone normally but cannot respond to it, resulting in near-zero IGF-1 levels throughout life. A cohort of approximately 230 Laron syndrome patients in Ecuador has been followed for decades, and the finding is striking: despite being shorter and having obesity and metabolic complications, these individuals have virtually no cancer incidence. This natural experiment provides the strongest evidence that IGF-1 plays a causal role in human cancer development.

Acromegaly Data

Acromegaly (chronic GH excess, usually from a pituitary tumor) provides the mirror image. Patients with acromegaly have chronically elevated IGF-1 levels and show increased rates of colorectal cancer, thyroid cancer, and possibly breast cancer. Lonergan et al. (2025) described a case of adrenocortical carcinoma with IGF-2 hypersecretion, illustrating how IGF system dysregulation connects to malignancy even outside the classical IGF-1 pathway.^[5]

What This Means for Growth Hormone Peptide Users

Growth hormone secretagogues (GHRPs like GHRP-2 and GHRP-6, GHRH analogs like CJC-1295 and sermorelin, and the oral secretagogue MK-677) elevate GH, which elevates IGF-1. The degree of IGF-1 elevation depends on the compound, dose, frequency, and individual response. MK-677 at 25 mg daily typically raises IGF-1 by 40-80% over baseline. GHRP-6 and CJC-1295 combinations produce similar or greater elevations.

The critical question: does peptide-induced IGF-1 elevation carry the same cancer risk as naturally elevated IGF-1? The honest answer is that no one knows. There are no long-term cancer incidence studies in people using growth hormone secretagogues. The epidemiological data linking IGF-1 to cancer comes from naturally occurring variation in IGF-1 levels, not from pharmacologically induced elevation. For a detailed analysis of the long-term data gap, see long-term GH peptide safety.

Several factors complicate direct extrapolation. GH peptides produce pulsatile IGF-1 elevation (peaks and troughs) rather than the sustained elevation seen in acromegaly. The duration of exposure matters: most peptide users cycle their compounds for weeks to months, not years to decades. And the magnitude of IGF-1 elevation from peptides is typically modest compared to acromegaly, where IGF-1 may be 3-5 times the upper normal limit.

Cui et al. (2018) added an unexpected wrinkle: GHRH agonistic analogs paradoxically inhibited hepatic and tumoral IGF-1 secretion in experimental models, through direct effects on liver and tumor cells that are independent of the pituitary GH pathway.^[3] This suggests that at least some growth hormone-axis peptides may have anti-tumor effects that partly offset the IGF-1-mediated pro-growth signal. This finding has not been confirmed in humans.

The Obesity-IGF-1-Cancer Triangle

Albini et al. (2025) reviewed the intersection of obesity, diabetes, and cancer risk, highlighting that the metabolic state associated with obesity (hyperinsulinemia, elevated IGF-1, chronic inflammation) creates a pro-tumorigenic environment.^[1] This context is relevant because many growth hormone peptide users are also pursuing body composition changes that reduce obesity, which would be expected to lower cancer risk. The net effect of a compound that simultaneously raises IGF-1 (theoretically increasing risk) while reducing visceral fat (reducing risk) is genuinely uncertain.

Daniel et al. (2025) found that semaglutide treatment over one year altered circulating IGFBP levels in type 2 diabetes patients.^[2] Since IGFBPs regulate IGF-1 bioavailability, GLP-1 RA-mediated changes in IGFBP profiles could modify cancer risk in ways that are not captured by measuring total IGF-1 alone. This suggests that the IGF system is more dynamic and interconnected with other metabolic pathways than simple IGF-1 measurement reflects.

Aguiar-Oliveira et al. (2026) reviewed growth hormone and IGF-1 actions in the brain, noting that the GH/IGF-1 axis has neuroprotective effects that must be weighed against oncological concerns.^[6] The balance between IGF-1's beneficial effects (tissue repair, cognitive function, bone density, muscle maintenance) and its theoretical cancer risk is the central tension in growth hormone peptide pharmacology.

The Ghrelin Receptor Paradox: Cancer Cachexia Treatment

One area where the GH/IGF-1 axis intersects directly with cancer is cachexia, the muscle-wasting syndrome that affects up to 80% of advanced cancer patients and contributes to approximately 20% of cancer deaths. Nishie et al. (2022) reviewed anamorelin, a ghrelin receptor agonist that stimulates appetite and growth hormone release, which has been approved in Japan for cancer cachexia treatment.^[7]

Anamorelin raises IGF-1 levels, which is exactly the concern discussed throughout this article. Yet it is being used in patients who already have cancer, on the rationale that the benefits of preventing cachexia-related death outweigh the theoretical risk of promoting existing tumor growth. Clinical trials of anamorelin in cancer patients have not shown accelerated tumor progression, though the follow-up periods have been relatively short. This clinical reality complicates the narrative that elevated IGF-1 automatically promotes cancer: in the real world, the context matters enormously.

Luo et al. (2025) demonstrated a different approach to targeting the metabolic-cancer connection: a peptide-based strategy that inhibited SREBP activation (a master regulator of lipid synthesis in tumor cells), suppressing both tumor lipogenesis and growth.^[8] This illustrates that the peptide-cancer relationship is not one-dimensional. Some peptides promote growth pathways that could theoretically benefit tumors. Others directly target tumor metabolism. The biological context and specific mechanism determine whether a peptide is friend or foe in oncology.

Practical Considerations for Monitoring

For individuals using growth hormone secretagogues, several practical points emerge from the evidence:

Baseline and periodic IGF-1 testing is standard clinical practice. IGF-1 levels should ideally remain within the age-adjusted reference range. Supraphysiological IGF-1 (above the upper limit for age) represents the highest-risk zone based on epidemiological data, though the absolute risk increase is modest even at elevated levels.

Cancer screening adherence becomes more relevant for GH peptide users. Standard age-appropriate cancer screening (colonoscopy, mammography, PSA monitoring) is particularly valuable for anyone chronically elevating IGF-1, because early detection offsets theoretical risk far more effectively than avoiding the peptide entirely.

Duration of use is a critical variable. The epidemiological associations between IGF-1 and cancer are based on lifelong endogenous levels. Whether short-term peptide cycling (8-12 weeks) carries meaningful risk is unknown, but it is biologically plausible that shorter exposure poses less risk than chronic daily use over years.

Family history matters. Individuals with first-degree relatives who had colorectal, breast, or prostate cancer carry higher baseline risk, and adding IGF-1 elevation on top of genetic predisposition could theoretically compound that risk. This factor is relevant to risk-benefit discussions but has not been specifically studied in the context of GH peptide use. The interaction between genetic cancer susceptibility and pharmacological IGF-1 elevation is one of the most important unanswered questions in growth hormone peptide safety research.

For related coverage on growth hormone secretagogue risk profiles and how GHRPs activate the ghrelin receptor, see our dedicated articles.

The Bottom Line

Epidemiological evidence consistently associates higher IGF-1 levels with modest increases in colorectal, breast, and prostate cancer risk. The Laron syndrome natural experiment and acromegaly data support a causal role for IGF-1 in cancer development. For growth hormone peptide users, the direct relevance is uncertain: no long-term cancer outcome data exists for GH secretagogue users, the magnitude and pattern of IGF-1 elevation differs from the conditions studied epidemiologically, and some GH-axis peptides paradoxically inhibit tumor IGF-1 secretion. The evidence warrants caution and monitoring but does not establish that GH peptide use causes cancer.

Frequently Asked Questions

Does IGF-1 cause cancer?

IGF-1 promotes cell growth through the PI3K/AKT signaling pathway, and higher circulating levels are associated with 9-15% increased risk per standard deviation for colorectal, breast, and prostate cancer in large epidemiological studies. The Laron syndrome natural experiment (near-zero IGF-1, virtually no cancer) supports a causal role. However, IGF-1 is one of many factors in cancer development, and most people with high-normal IGF-1 levels do not develop cancer.^[1]

Do growth hormone peptides increase cancer risk?

No long-term cancer outcome studies exist for growth hormone secretagogue users. GH peptides elevate IGF-1, and higher IGF-1 is epidemiologically associated with modest cancer risk increases. However, peptide-induced IGF-1 elevation is typically pulsatile and moderate, unlike the sustained extreme elevation in acromegaly. The direct cancer risk from GH peptides remains theoretically plausible but clinically unproven.^[3]

What is Laron syndrome and why does it matter for IGF-1 research?

Laron syndrome is a genetic condition where growth hormone receptor deficiency results in near-zero IGF-1 levels throughout life. A cohort of approximately 230 patients in Ecuador has virtually no cancer incidence despite obesity and other health complications. This natural experiment provides the strongest evidence that IGF-1 plays a causal role in human cancer development.

Should I monitor IGF-1 levels if using growth hormone peptides?

Monitoring IGF-1 is the standard approach for anyone using compounds that elevate growth hormone. Keeping IGF-1 within the upper-normal age-adjusted range (rather than supraphysiological levels) is the conservative approach favored by clinicians who prescribe growth hormone therapeutically. There is no established "safe" IGF-1 level for cancer risk, but the epidemiological data shows risk increases with levels above the population mean.^[1]

Does MK-677 raise IGF-1 enough to increase cancer risk?

MK-677 at 25 mg daily typically raises IGF-1 by 40-80% over baseline. Whether this magnitude of elevation increases cancer risk is unknown because no long-term cancer outcome data exists for MK-677 users. The epidemiological associations between IGF-1 and cancer are based on naturally occurring variation, not pharmacologically induced elevation. The risk, if any, likely depends on the duration of use.

Can some growth hormone peptides actually protect against cancer?

Unexpectedly, GHRH agonistic analogs have been shown to paradoxically inhibit hepatic and tumoral IGF-1 secretion in experimental models, through direct effects on cells independent of the pituitary pathway.^[3] This does not mean GH peptides prevent cancer, but it complicates the assumption that all GH-axis compounds uniformly increase cancer risk through IGF-1 elevation.